Search hospitals

>

California

>

Beverly Hills

Tower Hematology Oncology Medical Group

Claim this profile

Beverly Hills, California 90211

Conducts research for Lung Cancer

Conducts research for Cancer

Conducts research for Lymphoma

Conducts research for Non-Hodgkin's Lymphoma

Conducts research for Leukemia

29 reported clinical trials

2 medical researchers

Photo of Tower Hematology Oncology Medical Group in Beverly HillsPhoto of Tower Hematology Oncology Medical Group in Beverly HillsPhoto of Tower Hematology Oncology Medical Group in Beverly Hills

Summary

Tower Hematology Oncology Medical Group is a medical facility located in Beverly Hills, California. This center is recognized for care of Lung Cancer, Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Leukemia and other specialties. Tower Hematology Oncology Medical Group is involved with conducting 29 clinical trials across 47 conditions. There are 2 research doctors associated with this hospital, such as Omid Hamid and Peter Rosen, MD.

Top PIs

Clinical Trials running at Tower Hematology Oncology Medical Group

Gaucher Disease

Gaucher's disease

Gaucher disease

Image of trial facility.

Registry

for Gaucher Disease

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives of the Registry are: * To enhance understanding of the variability, progression, identification, and natural history of Gaucher disease, with the ultimate goal of better guiding and assessing therapeutic intervention. * To assist the Gaucher medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care. * To characterize the Gaucher disease population. * To evaluate the long-term effectiveness of imiglucerase and of eliglustat. Gaucher Pregnancy Sub-registry: The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Gaucher disease during pregnancy, regardless of whether they receive disease-specific therapy. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician.If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.

Recruiting

1 award

N/A

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Tower Hematology Oncology Medical Group?